Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69.
周四，再生元制药公司（纳斯达克股票代码：REGN）报告第三季度调整后每股收益为12.46美元，同比增长8%，超过市场预期的11.69美元。
The company reported sales of $3.72 billion, up 11%, beating the consensus of $3.67 billion.
该公司报告的销售额为37.2亿美元，同比增长11%，超过市场预期的36.7亿美元。
"Regeneron had a strong third quarter marked by 11% revenue growth. We continued to deepen the impact of our commercialized medicines this quarter, with ongoing leadership for our retinal franchise, expanded global reach of Libtayo, and notable growth from Dupixent," said Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron.
“再生元在第三季度取得了强劲增长，营业收入增长11%。在本季度，我们继续加深了商业化药品的影响力，在视网膜产品系列方面保持领先地位，扩大了Libtayo的全球影响力，并在Dupixent方面取得了显著增长，”再生元制药公司董事会联席主席、总裁兼首席执行官Leonard S. Schleifer表示。
Also Read: Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
此外阅读：再生元首席警告流行的减肥药（如奥泽帕）存在健康风险，表示公司旨在保持肌肉并针对其肥胖药品进行了目标定位。
"Our strong third quarter financial performance was highlighted by double-digit revenue growth and continued investment in our growing pipeline," said Christopher Fenimore, Senior Vice President, Finance and Chief Financial Officer of Regeneron.
“我们强劲的第三季度财务表现突显出两位数营业收入增长以及持续对日益增长的项目组合的投资，”再生元制药公司高级副总裁、财务和首席财务官Christopher Fenimore表示。
Third quarter 2024 U.S. net sales for Eylea HD and Eylea increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from Eylea HD.
2024年第三季度，Eylea HD和Eylea的美国净销售额较2023年第三季度增长3%，达到15.4亿美元，其中包括来自Eylea HD的39200万美元。
A lower net selling price adversely impacted the net product sales of EYLEA in the third quarter of 2024.
较低的净销售价格对2024年第三季度EYLEA的净产品销售额产生了不利影响。
Libtayo global net sales increased by 25% to $289 million.
Libtayo的全球净销售额增长了25%，达到28900万美元。
Sanofi SA (NASDAQ:SNY) collaboration revenue increased from $1.06 billion to $1.26 billion.
赛诺菲安万特(纳斯达克:SNY) 合作营业收入从$10.6亿增至$12.6亿。
The company said its obesity clinical program is now enrolling.
该公司表示其肥胖症临床项目现已开始招募。
In its earnings presentation, Regeneron said Phase 2 study to investigate if addition of trevogrumab (anti-myostatin) to Novo Nordisk A/S' (NYSE:NVO) semaglutide with and without garetosmab (antiactivin A) improves the quality of weight loss and/or improves maintenance of weight loss post semaglutide discontinuation.
在其收益报告中，再生元制药公司表示第2阶段研究旨在调查将特鲁沃格鲁麻布(抗肌肉生成素)添加到Novo Nordisk A/S(纽约交易所:NVO)的塞马格鲁蒂德，带或不带加里托麦这一研究是否改善减重质量和/或改善塞马格鲁蒂德停药后的减重维持情况。
Safety and tolerability data for high-dose trevogrumab in healthy volunteers showed no new safety signals.
健康志愿者中高剂量特鲁沃格鲁麻布的安全性和耐受性数据未显示出新的安全信号。
The company is on track to complete enrollment by year-end 2024; results for both primary endpoints are expected in 2H25.
该公司将按计划在2024年底前完成招募工作；预计两个主要终点的结果将在2025年下半年公布。
Price Action: REGN stock is down 10.7% at $824.28 at last check Thursday.
股价走势：REGN股票最新报价下跌10.7%，为每股$824.28，截至周四最后交易。
Photo via Shutterstock
图片来自shutterstock。
- Cigna's Q3 Profit Beats Street On Strong Demand For Pharmacy Benefit Management's Specialty Drugs, New Clients
- 辛格第三季度利润超过预期，受制药管理特殊药品强劲需求和新客户推动
